Overview

Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic Study of AL001 in Patients With Alzheimer's Disease

Status:
Not yet recruiting
Trial end date:
2023-04-28
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, single-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001. Approximately 40 participants will be randomly assigned to receive study drug (active AL001) or placebo. The study consists of a 4-week screening period, a 14-day treatment period, and a 42-day follow-up period.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Alzamend Neuro, Inc.